학술논문
Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.
Document Type
Article
Author
Source
Infection; Aug2023, Vol. 51 Issue 4, p851-858, 8p, 3 Charts
Subject
Language
ISSN
03008126
Abstract
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)